The signal strength of Relugolix (Orgovyx®) at the System Organ Class (SOC) level.

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Ruibo Li (2063167) (author)
مؤلفون آخرون:	Xi Chen (35903) (author), Yujie Wang (308942) (author)
منشور في:	2024
الموضوعات:	Medicine Cell Biology Pharmacology Biotechnology Immunology Cancer Biological Sciences not elsewhere classified ‘ primary suspected take timely prevention reporting odds ratios rare adverse events prostate cancer based may remain undetected avoid serious consequences 26 organ systems adverse events analysis first 30 days unexpected significant aes ps )’ aes aes occurred within market data analysis faers database covering ensure drug safety disproportionality analysis safety information faers database 60 days aes associated treatment measures third quarter side effects potential risks fourth quarter four algorithms comprehensively analyze clinical trials bcpnn ), 397 reports 189 reports
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level.